NAME: Jin, Guangyi

POSITION TITLE: Professor of Pharmaceutical Sciences; Associate Director, Cancer Research Center, Shenzhen University School of Medicine; Director, State-Regional Joint Engineering Laboratory of the Key Technology in Synthetic Biology of Medicine, Shenzhen University

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

A.   Personal Statement

I have long been working on cross disciplinary studies of chemical and biological macromolecular drugs, predominantly focusing on the design and synthesis of immunological anti-cancer and anti-viral drugs and vaccines, and research and development in cell and molecular biology. I engage in the study of synthetic drugs in immune anticancer, immune anti-viral, pharmacological and pharmacodynamic studies, and also mass spectrometry and nuclear magnetic resonance application to identify bioactive substances. I am conducting a number of national and regional key projects as a Principal Investigator, in which new technology on tumor immunotherapy is under clinical investigation.

B.   RESEARCH INTERESTS

Tolllike receptor agonist synthesis and its application to antibody induction, biological immunotherapy and innovative vaccines; Wnt signaling pathway inhibitor synthesis and its application to cancer therapy; Lumazine synthase inhibitor synthesis and its application as new antibiotics.

 C.Positions and Honors 

01/2009 – present Professor of Pharmaceutical Sciences; Associate Director,  Cancer Research Center, Shenzhen University

D.   Representative publications (*: corresponding/co-corresponding author)

[1] Dong Gao, Yu Liu, Yuwen Diao, Ningning Gao, Zhulin Wang, Wenqi Jiang, and Guangyi Jin*， “Synthesis and Evaluation of Conjugates of Novel TLR7 Inert Ligands as Self-Adjuvanting Immunopotentiators.” ACS Med. Chem. Lett., 2015, 6(3):249–253.

[2] Jiang Zhu，Shiping He，Jie Du，Zhulin Wang，Wang Li，Xianxiong Chen，Wenqi Jiang，Duo Zheng and Guangyi Jin*， “Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma.”  Journal of Hematology & Oncology. 2015, Mar 4;8(1):21. doi: 10.1186/s13045-015-0121-9.

[3] Dong Gao, Yuwen Diao, Wang Li, Ningning Gao, Yu Liu, Zhulin Wang, Wenqi Jiang and Guangyi Jin*. “Toll-Like Receptor 7 Inactive Ligands Enhanced Cytokine Induction by Conjugation to Weak Antigens.” ChemMedChem.2015, Apr 16. doi: 10.1002/cmdc.201500088

[4] Guimiao Lin，Xiaomei Wang，Wanxian Yi，Chuanxia Zhang，Gaixia Xu，Xiaomei Zhu，Zhiming Cai，Yu Liu，Yuwen Diao，Marie Chia-Mi Lin，and Guangyi Jin*  “A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma” Journal of Translational Medicine,2015, 13(1):166.

[5] Wang XD, Gao NN, Diao YW, Liu Y, Gao D, Li W, Wan YY, Zhong JJ, Jin GY*. “Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects.” World J Gastroenterol.2015 Jul 14;21(26):8052-60. doi: 10.3748/wjg.v21.i26.8052.

[6] Wang X, Diao Y, Liu Y, Gao N, Gao D, Wan Y, Zhong J, Jin G*. “Synergistic apoptosis-inducing effect of aspirin and isosorbide mononitrate on human colon cancer cells.” Mol Med Rep.2015 Sep;12(3):4750-8. doi: 10.3892/mmr.2015.3963. Epub 2015 Jun 18

[7]  Chen T, Hu Y, Lin X, Huang X, Liu B, Leung P, Chan SO, Guo D, Jin G*. “Dopamine signaling regulates the projection patterns in the mouse chiasm.”

 Brain Res. 2015，Nov 2; 1625: 324-36

[8]  Yuwen Diao, Xiaodong Wang, Yanyan Wan, Jingjing Zhong, Dong Gao, Yu Liu, Ningning Gao, Wang Li, Bing Liu, Xinping Huang, Zhenchao Jin, Boya Peng, Zhulin Wang, Li Fu, Siping Chen, Guangyi Jin*. “Antitumor activity of a novel small molecule TLR7 agonist via immune response induction and tumor microenvironment modulation”. Oncology Reports,  2016，35: 793-800

[9]  Yongkun Du , Taofeng Du , Yunpeng Shi , Angke Zhang, Chong Zhang , Yuwen Diao, Guangyi Jin* , En-Min Zhou*. “Synthetic Toll-like receptor 7 ligand inhibits porcine reproductive and respiratory syndrome virus infection in primary porcine alveolar macrophages”. Antiviral Research, 2016, Apr 11; 131:9-18.

[10]  Dong Gao, Juan Zeng, Xiaodong Wang, Yu Liu, Wang Li, Yunlong Hu, Ningning Gao, Yuwen Diao, Zhulin Wang, Wenqi Jiang, Jinhua Chen , Guangyi Jin*. “Conjugation of weak ligands with weak antigens to activate TLR-7: A step toward better vaccine adjuvants” European Journal of Medicinal Chemistry, 2016, 120 (14) , 111–120.

[11] Tingting Chen, Yunlong Hu, Bin Liu, Xinping Huang, Ningning Gao, Zhenchao Jin，Tieliu Jia, Deyin Guo, Guangyi Jin*. “Synthetic Toll-like Receptor 7 Agonist as a conjugated adjuvant enhances the Th1 type immunogenicity of Influenza Virus Vaccine”. International Journal of Clinical and Experimental Pathology, 2016; 9 (4): 4790-4795.

[12] Yunlong Hu, Tingting Chen, Song Liu, Bin Liu, Hongxue Meng, Lei Zhang, Di Sun, Yong Dai, Deyin Guo, Xiaoming Jin, Guangyi Jin*, Fengmin Zhang*. “Gelsolin deposits in renal tissues of the patients with lupus nephritis”. International Journal of Clinical and Experimental Pathology, 2016; 9 (5):5413-5420.

[13] Tingting Chen, Yunlong Hu, Bin Liu, Xinping Huang, Qin Li, Ningning Gao, Zhenchao Jin, Tieliu Jia, Deyin Guo, Guangyi Jin*. “Combining thioridazine and loratadine for the treatment of gastrointestinal tumor”. Oncology letters , 2016 (accepted).

[14] Liu B, Huang X, Hu Y, Chen T, Peng B, Gao N, Jin Z, Jia T, Zhang N, Wang Z, Jin G*. “Ethacrynic acid improves the antitumor effects of irreversible epidermal growth factor receptor tyrosine kinase inhibitors in breast cancer”. Oncotarget , 2016 Jul 26. doi: 10.18632/oncotarget.10846. [Epub ahead of print]

[15] Ningning Gao, Jingjing Zhong, Xiaodong Wang, Zhenchao Jin, Wang Li, Yu Liu, Yuwen Diao, Zhulin Wang, Wenqi Jiang & Guangyi Jin*.“Immunomodulatory and Antitumor Efects of a Novel TLR7 Agonist Combined with Lapatinib”. Scientific Reports, 2016 Dec 21;6:39598. doi: 10.1038/srep39598

[16] Chi H, Li C, Zhao FS, Zhang L, Ng TB, Jin G*, Sha O*. “Anti-tumor Activity of Toll-Like Receptor 7 Agonists”. Front Pharmacol. 2017 May 31;8:304. doi: 10.3389/fphar.2017.00304

 E. Resrarch Support (As first PI)

1. The National Natural Science Foundation of China:（81072518）, 2010—2013 （280,000 RMB）

2. The Hong Kong Shenzhen cooperation project: （ZYB200907090134A）, 2009—2012 （400,000 RMB）

3.  Shenzhen city basic Sciences research projects:（JC201005250060A）,    2010—2013（600,000 RMB）

4. The National Natural Science Foundation of China:（81273374）, 2013—2016 （670,000 RMB）

5. Major key projects of Shenzhen City: Tumor vaccine research Based on Toll like receptor 7 (TLR7) (JSGG20120614151715670), 2012—2015（5,000,000 RMB）

6. Shenzhen synthetic biology engineering laboratory（Shenzhen Development and Reform Commission【2012】No. 553）, 2012—2014（5,000,000 RMB）

7. Nanshan District core technology breakthrough project：Study on tumor immunotherapy specificity and the new individual therapeutical technology(KC2013JSJS0017A), 2013—2016（1,500,000 RMB）

8. The State and local joint engineering laboratory of the key technology in Synthetic biology medicine（National Development and Reform Commission：[2015] No. 581；Shenzhen Development and Reform Commission: [2015] No.945）2015—2017 （3,500,000 RMB）

9.  Major industrial projects of Shenzhen City

“Research on the key technology of new adjuvant of hepatitis B vaccine”（JSGG20150602150258354）2015—2018  （2,250,000 RMB）